The addition of D1 peptide to IL-13-treated cells caused a near complete inhibition of the IL-13 prometastatic effects in both colon cancer cell lines, being particularly effective in the inhibition of the invasiveness capacity (Fig. 2a). Here, IL13 is linked to malignant colon neoplasm.